Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672698 | 0.94 | — | — | |
| SCHEMBL1983990 | 0.94 | CYP2C9 (0.39) | LMNACYP2C9TSHR | |
| SCHEMBL19645307 | 0.94 | — | — | |
| SCHEMBL191998 | 0.94 | — | — | |
| SCHEMBL29151913 | 0.94 | CYP2C9 (0.39) | LMNACYP2C9TSHR | |
| SCHEMBL285299 | 0.94 | — | — | |
| SCHEMBL13889160 | 0.94 | — | — | |
| SCHEMBL351728 | 0.94 | — | — | |
| SCHEMBL36515 | 0.94 | — | — | |
| SCHEMBL5351420 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9587147-B2 | Pressure-sensitive adhesive compositions, polarizers and liquid crystal displays comprising the same | LG CHEM, LTD. (KR) | 2017-03-07 | — | — | US | claimed |
| EP-2230287-B1 | PRESSURE-SENSITIVE ADHESIVE COMPOSITIONS, POLARIZERS AND LIQUID CRYSTAL DISPLAYS COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2013-06-12 | — | — | EP | claimed |
| US-20110032455-A1 | PRESSURE-SENSITIVE ADHESIVE COMPOSITIONS, POLARIZERS AND LIQUID CRYSTAL DISPLAYS COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2011-02-10 | — | — | US | claimed |
| EP-2230287-A2 | PRESSURE-SENSITIVE ADHESIVE COMPOSITIONS, POLARIZERS AND LIQUID CRYSTAL DISPLAYS COMPRISING THE SAME | LG Chem, Ltd. (KR) | 2010-09-22 | — | — | EP | claimed |
| US-9587147-B2 | Pressure-sensitive adhesive compositions, polarizers and liquid crystal displays comprising the same | LG CHEM, LTD. (KR) | 2017-03-07 | — | — | US | disclosed |
| US-9011734-B2 | Ligand exchange thermochromic, (LETC), systems | PLEOTINT, L.L.C. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2230287-B1 | PRESSURE-SENSITIVE ADHESIVE COMPOSITIONS, POLARIZERS AND LIQUID CRYSTAL DISPLAYS COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2013-06-12 | — | — | EP | disclosed |
| EP-2082005-B9 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT LLC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8431045-B2 | Ligand exchange thermochromic systems and high ε ligands for same | PLEOTINT, L.L.C. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2540321-A1 | Bis Tridentate W3O2 Clusters for X-Ray imaging | Bayer Intellectual Property GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20120292581-A1 | LIGAND EXCHANGE THERMOCHROMIC SYSTEMS AND HIGH E LIGANDS FOR SAME | PLEOTINT, LLC (US) | 2012-11-22 | — | — | US | disclosed |
| EP-1487789-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | Charterhouse Therapeutics Ltd. (GB) | 2004-12-22 | — | — | EP | disclosed |
| EP-1456163-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | Charterhouse Therapeutics Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-20030219404-A1 | Branched polyalkylene glycols | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| WO-2003082813-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | CHARTERHOUSE THERAPEUTICS LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003051807-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | CHARTERHOUSE THERAPEUTICS LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| US-20030035917-A1 | Image making medium | HYMAN SYDNEY (US) | 2003-02-20 | — | — | US | disclosed |
| EP-1270642-A1 | BRANCHED POLYALKYLENE GLYCOLS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001030745-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219404-A1 | Branched polyalkylene glycols | LNPEP, ANPEP, BCAT1 | LMNA 696/4885CYP2C9 4377/4885TSHR 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.